Portal de Periódicos da CAPES

Quality Indicators for the Care of Stroke and Atrial Fibrillation in Vulnerable Elders

2007; Wiley; Volume: 55; Issue: s2 Linguagem: Inglês

10.1111/j.1532-5415.2007.01352.x

1532-5415

Eric M. Cheng, Constance H. Fung,

Stroke Rehabilitation and Recovery

Journal of the American Geriatrics SocietyVolume 55, Issue s2 p. S431-S437 Quality Indicators for the Care of Stroke and Atrial Fibrillation in Vulnerable Elders Eric M. Cheng MD, MS, Eric M. Cheng MD, MS From the *Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California†David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California‡RAND, Santa Monica, CaliforniaSearch for more papers by this authorConstance H. Fung MD, MSHS, Constance H. Fung MD, MSHS From the *Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California†David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California‡RAND, Santa Monica, CaliforniaSearch for more papers by this author Eric M. Cheng MD, MS, Eric M. Cheng MD, MS From the *Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California†David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California‡RAND, Santa Monica, CaliforniaSearch for more papers by this authorConstance H. Fung MD, MSHS, Constance H. Fung MD, MSHS From the *Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California†David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California‡RAND, Santa Monica, CaliforniaSearch for more papers by this author First published: 01 October 2007 https://doi.org/10.1111/j.1532-5415.2007.01352.xCitations: 14 Address correspondence to Eric M. Cheng, MD, MS, 11301 Wilshire Boulevard, ML 127, B500, Department of Neurology, Los Angeles, CA 90073. E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Heart Disease and Stroke Statistics. Dallas, TX: American Heart Association, 2005. 2 Rothwell PM, Eliasziw M, Gutnikov SA et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361: 107–116. 3 Chaturvedi S, Bruno A, Feasby T et al. Carotid endarterectomy—an evidence-based review: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65: 794–801. 4 Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409–e449. 5 Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 429S–456S. 6 Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231–1265. 7 Benavente O, Hart R, Koudstaal P et al. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000; (2):CD001925. 8 Benavente O, Hart R, Koudstaal P et al. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000; (2):CD001927. 9 Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2004; (2):CD000185. 10 Koudstaal PJ. Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000; (2):CD000186. 11 Gage BF, Van Walraven C, Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287–2292. 12 Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870. 13 Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–638. 14 Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540–546. 15 Brass LM, Krumholz HM, Scinto JM et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–2389. 16 Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–691. 17 The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857–865. 18 Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745–752. 19 Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: Physicians' fears often unfounded. Arch Intern Med 2003; 163: 1580–1586. 20 Man-Son-Hing M, Nichol G, Lau A et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677–685. 21 Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 483S–512S. 22 Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Stroke prevention in patients with nonvalvular atrial fibrillation. Neurology 1998; (51): 671–73. 23 Wolf PA, Clagett GP, Easton JD et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999; 30: 1991–1994. 24 Snow V, Weiss KB, LeFevre M et al. Management of newly detected atrial fibrillation: A clinical practice guideline from the AAFP and ACP. Ann Intern Med 2003; 139: 1009–1017. 25 Management of Stroke Rehabilitation in Primary Care Summary. VA/DoD Clinical Practice Guideline. Washington, DC: VA Employee Education System, Department of Defense, 2002. 26 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86. 27 Diener HC, Cunha L, Forbes C et al. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13. 28 Halkes PH, Van Gijn J, Kappelle LJ et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006; 367: 1665–1673. 29 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339. 30 Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–337. 31 Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–1451. 32 Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–1316. 33 Amarenco P, Bogousslavsky J, Callahan A et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559. 34 Collins R, Armitage J, Parish S et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–767. 35 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7–22. 36 Stroke Council, American Heart Association; American Stroke Association. Statins after ischemic stroke and transient ischemic attack: An advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2004; 35: 1023. 37 Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298: 789–794. 38 Wolf PA, D'Agostino RB, Kannel WB et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988; 259: 1025–1029. 39 Kawachi I, Colditz GA, Stampfer MJ et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993; 269: 232–236. 40 Saunders DH, Greig CA, Young A et al. Physical fitness training for stroke patients. Cochrane Database Syst Rev 2004; (1):CD003316. 41 Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: A meta-analysis. Stroke 2003; 34: 2475–2481. 42 Reynolds K, Lewis B, Nolen JD et al. Alcohol consumption and risk of stroke: A meta-analysis. JAMA 2003; 289: 579–588. 43 Viscoli CM, Brass LM, Kernan WN et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243–1249. 44 Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale. Ann Intern Med 2002; 137: 834–839. 45 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–1587. 46 Greenlund KJ, Neff LJ, Zheng ZJ et al. Low public recognition of major stroke symptoms. Am J Prev Med 2003; 25: 315–319. 47 Schneider AT, Pancioli AM, Khoury JC et al. Trends in community knowledge of the warning signs and risk factors for stroke. JAMA 2003; 289: 343–346. 48 Reeves MJ, Hogan JG, Rafferty AP. Knowledge of stroke risk factors and warning signs among Michigan adults. Neurology 2002; 59: 1547–1552. 49 Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services. Healthy People [on-line]. Available at http://www.healthypeople.gov/Data Accessed September 6, 2005. 50 Sandercock P, Gubitz G, Foley P et al. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2003; (2):CD000029. 51 Coull BM, Williams LS, Goldstein LB et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Neurology 2002;59: 13–22. 52 Adams HP Jr, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056–1083. 53 Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768–774. 54 Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025. 55 Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245–1251. 56 Clark WM, Wissman S, Albers GW et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019–2026. 57 Adams HP Jr, Brott TG, Furlan AJ et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996; 27: 1711–1718. 58 Practice advisory: Thrombolytic therapy for acute ischemic stroke–summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 47: 835–839. 59 Hackett ML, Yapa C, Parag V et al. Frequency of depression after stroke: A systematic review of observational studies. Stroke 2005; 36: 1330–1340. 60 Hackett ML, Anderson CS, House AO. Management of depression after stroke: A systematic review of pharmacological therapies. Stroke 2005; 36: 1098–1103. 61 Greener J, Enderby P, Whurr R. Speech and language therapy for aphasia following stroke. Cochrane Database Syst Rev 1999; (2):CD000425. 62 Bhogal SK, Teasell R, Speechley M. Intensity of aphasia therapy, impact on recovery. Stroke 2003; 34: 987–993. 63 Bath PM, Bath FJ, Smithard DG. Interventions for dysphagia in acute stroke. Cochrane Database Syst Rev 1999; (2):CD000323. 64 Smithard DG, O'Neill PA, Parks C et al. Complications and outcome after acute stroke. Does dysphagia matter? Stroke 1996; 27: 1200–1204. 65 Daniels SK, Ballo LA, Mahoney MC et al. Clinical predictors of dysphagia and aspiration risk: Outcome measures in acute stroke patients. Arch Phys Med Rehabil 2000; 81: 1030–1033. 66 DePippo KL, Holas MA, Reding MJ. Validation of the 3-oz water swallow test for aspiration following stroke. Arch Neurol 1992; 49: 1259–1261. 67 Teramoto S, Fukuchi Y. Detection of aspiration and swallowing disorder in older stroke patients: Simple swallowing provocation test versus water swallowing test. Arch Phys Med Rehabil 2000; 81: 1517–1519. 68 Daniels SK, Brailey K, Priestly DH et al. Aspiration in patients with acute stroke. Arch Phys Med Rehabil 1998; 79: 14–19. 69 Aviv JE. Prospective, randomized outcome study of endoscopy versus modified barium swallow in patients with dysphagia. Laryngoscope 2000; 110: 563–574. 70 Therapy-based rehabilitation services for stroke patients at home. Cochrane Database Syst Rev 2002; (1):CD002925. 71 Kwakkel G, Van Peppen R, Wagenaar RC et al. Effects of augmented exercise therapy time after stroke: A meta-analysis. Stroke 2004; 35: 2529–2539. 72 Steultjens EM, Dekker J, Bouter LM et al. Occupational therapy for stroke patients: A systematic review. Stroke 2003; 34: 676–687. 73 Walker MF, Leonardi-Bee J, Bath P et al. Individual patient data meta-analysis of randomized controlled trials of community occupational therapy for stroke patients. Stroke 2004; 35: 2226–2232. Citing Literature Volume55, Issues2October 2007Pages S431-S437 ReferencesRelatedInformation